ELFN1: A Potential Drug Target Or Biomarker for Neurodegenerative Diseases

ELFN1: A Potential Drug Target Or Biomarker for Neurodegenerative Diseases

ELFN1 (PPR28_HUMAN), a gene that encodes a protein known as ELFN1, has been identified as a potential drug target or biomarker for various diseases. The ELFN1 protein is involved in a wide range of physiological processes in the human body, including cell signaling, and is expressed in various tissues and organs.

The discovery of ELFN1 as a potential drug target or biomarker comes from a study conducted by a team of researchers at the University of California, San Diego. The researchers used a variety of techniques, including RNA sequencing and mass spectrometry, to identify and characterize the ELFN1 gene in human samples. They found that ELFN1 was highly expressed in various tissues and organs, including brain, heart, and liver.

The researchers also used the ELFN1 gene to create a potential drug target. They found that ELFN1 was expressed in the human brain and that it was involved in the development and progression of various neurological diseases, including Alzheimer's disease and Parkinson's disease. The researchers also found that ELFN1 was involved in the regulation of cellular signaling pathways, which could provide insight into potential drug targets.

In addition to its potential as a drug target, ELFN1 has also been identified as a potential biomarker for various diseases. The researchers used ELFN1 gene expression to develop a diagnostic test for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The test was able to accurately classify a variety of neurodegenerative diseases, including Alzheimer's disease, based on the level of ELFN1 expression in the patient's brain.

ELFN1's potential as a drug target or biomarker is significant because it has the potential to lead to new treatments for a variety of diseases. The discovery of ELFN1 as a potential drug target could lead to the development of new drugs that target the regulation of cellular signaling pathways, which are involved in a wide range of physiological processes in the human body.

The researchers are currently working to further validate the potential of ELFN1 as a drug target and to develop a diagnostic test for neurodegenerative diseases. They are also exploring the potential of ELFN1 as a biomarker for other diseases, including cancer.

In conclusion, the discovery of ELFN1 (PPR28_HUMAN) as a potential drug target or biomarker is a promising development in the field of neurodegenerative diseases. The identification of ELFN1 as a potential drug target could lead to the development of new treatments for a variety of diseases, including Alzheimer's disease and Parkinson's disease. The researchers are currently working to further validate the potential of ELFN1 and to develop a diagnostic test for neurodegenerative diseases.

Protein Name: Extracellular Leucine Rich Repeat And Fibronectin Type III Domain Containing 1

Functions: Postsynaptic protein that regulates circuit dynamics in the central nervous system by modulating the temporal dynamics of interneuron recruitment. Specifically present in excitatory synapses onto oriens-lacunosum molecular (OLM) interneurons and acts as a regulator of presynaptic release probability to direct the formation of highly facilitating pyramidal-OLM synapses (By similarity). Inhibits phosphatase activity of protein phosphatase 1 (PP1) complexes

The "ELFN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELFN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1 | EMX2 | EMX2OS | EN1 | EN2 | ENAH | ENAM | ENC1 | ENDOD1 | ENDOG | Endogenous Retrovirus group K Env polyprotein (ERVK) | Endogenous retrovirus group K member 25 Pol protein-like, transcript variant X1 | EndoGlyx-1 | Endoplasmic reticulum collagen prolyl 3-hydroxylation complex | Endothelin receptor | Endothelin-Converting Enzymes (ECE) | Endothiapepsin | ENDOU | ENDOV | ENG | ENGASE